pharma news today obesity drugs glp-1 today Roche was among the first pharmaceutical companies to research in the glucagon-like peptide-1 (GLP-1) class but abandoned the field after late-stage flops just before the latest boom began.⁠ ⁠ Having GLP-1 drugs changed the obesity

Description

Inflamm Bowel Dis 2024 Nov 27 [Epub]

AT has received honoraria from Boehringer Ingelheim Japan, Mochida, and Amgen

All three amylin products appear to have the potential to challenge tirzepatide on an efficacy/tolerability basis, so it will be interesting to see how Novo Nordisk and Eli Lilly position these products alongside their current GLP-1 offerings

Taken altogether, these mechanisms explain the clinical use of GLP-1RAs as beneficial treatment options for T2DM and obesity

This work was also supported by the National Key Research and Development Program of China (2018YFA0507001, 2018YFA0507000, 2018YFA0508100), the National Natural Science Foundation of China grants 31770898 (G.S.), 31900895 (L.Y.) and 81872915 (M.-W.W.), the National Science and Technology Major Project Key New Drug Creation and Manufacturing Program of China (2018ZX09735-001) and China Postdoctoral Science Foundation (2017M622365)